Sutures Versus Staples for Wound Closure in Orthopaedic Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01146236|
Recruitment Status : Unknown
Verified April 2011 by University of Manitoba.
Recruitment status was: Recruiting
First Posted : June 17, 2010
Last Update Posted : April 5, 2011
|Condition or disease||Intervention/treatment||Phase|
|Surgical Wound Infection||Device: Sutures Device: Staples||Not Applicable|
To date, there is no clear consensus on the method that is best for closure of surgical wounds in orthopaedic surgery. Orthopaedic surgeons have a multitude of wound closure habits. A recent meta-analysis comparing staples to sutures in wound closure demonstrated a three-fold increase in infection in stapled wounds compared to sutured wounds. The studies used in the meta-analysis were primarily of poor methodological quality.
A large, well-designed randomized, controlled trial is needed to guide orthopedic surgeons in their choice of wound closure materials. This study would attempt to provide information on the use of sutures versus skin staples and the effect on the development of surgical site infections in adults undergoing orthopaedic procedures.
A parallel group randomized controlled trial with institutional review board approval will be conducted. Patients will be randomized intraoperatively to have skin wounds closed with sutures or staples. Dressings will be used to maintain blinding of participants and outcome assessors. The primary outcome measure will be infections adjudicated by a blinded data safety monitoring committee. Suspected infections will be defined by: Use of antibiotics or reoperation for infection at the operative site within three months (six months for arthroplasty subgroup) The independent review, board blinded to treatment assignment, will adjudicate suspected infections based on clinical data. A cost analysis will also be performed to compare the costs associated with wounds closed with sutures and staples from a health care institution perspective.
All data will be analyzed by a blinded epidemiologist. Dichotomous primary and secondary outcome measures will be analyzed using the Chi-squared statistic. Continuous outcome measures will be analyzed using Student's t-test. Subgroup analysis will compare infection rates using sutures versus staples in each anatomic area (upper extremity, pelvis/acetabulum, hip/femur, knee, ankle). A further subgroup analysis will be conducted comparing trauma patients to elective patients. Non-infected revision surgery will also be compared to primary surgery.
It is hypothesized that wounds closed with sutures and staples will have similar infection rates as defined by the use of antibiotics or reoperation.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||2560 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Outcomes Assessor)|
|Official Title:||Sutures vs Staples for Wound Closure in Orthopaedic Surgery: A Randomized Controlled Trial|
|Study Start Date :||July 2010|
|Estimated Primary Completion Date :||September 2013|
|Estimated Study Completion Date :||December 2013|
Active Comparator: Sutures
Orthopedic surgical wound closed with sutures
Orthopedic surgical wounds closed with sutures
Active Comparator: Staples
Orthopedic surgical wound closed with metallic staples
Orthopedic surgical wounds closed with metallic staples
- Surgical site infection [ Time Frame: 6 months ]Suspected cases will be identified by one or all of the following: use of intravenous antibiotics, use of oral antibiotics (patient self-reported), re-operation at same site. A blinded committee will adjudicate each suspected case and determine true infections using available clinical information. Agreement will be determined by vote.
- Additional healthcare contact related to their surgery [ Time Frame: 6 months ]As defined by self-reported visits to other healthcare professionals.
- Dressing changes by homecare/patient at home [ Time Frame: 6 months ]Defined by homecare consult records and patient self-report
- Length of stay [ Time Frame: 6 months ]Based on admission and discharge dates
- Wound drainage [ Time Frame: 6 months ]As defined by necessity for dressing changes after 72 hours for fluid leakage
- Wound necrosis [ Time Frame: 6 months ]Evidence of marginal skin death at the surgical site as evidenced by skin slough, blackening or liquefaction
- Patient satisfaction with wound appearance [ Time Frame: 6 months ]Using visual analogue scale
- Visual analogue pain score for suture/staple removal [ Time Frame: 2 weeks post-operative ]Patients will rate the pain experienced in removing the wound closure materials in clinic prior to unblinding.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01146236
|Contact: Jesse Shantz, MD, MBAemail@example.com|
|Contact: James Vernon, MBBS, MScfirstname.lastname@example.org|
|Concordia Hip and Knee Institute||Recruiting|
|Winnipeg, Manitoba, Canada, R2K 2M9|
|Contact: Sarah Tran email@example.com|
|Sub-Investigator: Eric Bohm, MD|
|Sub-Investigator: Thomas Turgeon, MD MPH|
|Sub-Investigator: Colin Burnell, MD|
|Sub-Investigator: David R Hedden, MD|
|Health Sciences Centre||Recruiting|
|Winnipeg, Manitoba, Canada, R3A 1R9|
|Contact: Jesse A Shantz, MD MBA (204)996-0595 firstname.lastname@example.org|
|Sub-Investigator: Laurie W Barron, MD|
|Sub-Investigator: Ted V Tufescu, MD|
|Sub-Investigator: Christopher P Graham, MD|
|Sub-Investigator: Allan Hammond, MD|
|Sub-Investigator: Bradley D Pilkey, MD|
|Pan Am Clinic||Recruiting|
|Winnipeg, Manitoba, Canada, R3M 3E4|
|Contact: Leilanie Clayton, MSc email@example.com|
|Contact: Jeff Leiter, PhD firstname.lastname@example.org|
|Principal Investigator: Greg Stranges, MD|
|Sub-Investigator: Peter B MacDonald, MD|
|Sub-Investigator: Jason A Old, MD|
|Sub-Investigator: Tod Clark, MD MSc|
|Sub-Investigator: James H Dubberley, MD|
|Principal Investigator:||Jesse Shantz, MD, MBA||University of Manitoba|